Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 9/20 | 0.78 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.78 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.78 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788214 | 0.88 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CCNA2CDK2 | |
| SCHEMBL3712417 | 0.80 | MAPK8 (0.83) | MAPK8MAPK9MAPK10HRH3 | |
| SCHEMBL21216164 | 0.77 | MAPK9 (0.60) | MAPK8MAPK9MAPK10 | |
| SCHEMBL3713104 | 0.69 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CCNA2CDK2 | |
| SCHEMBL3713953 | 0.68 | POLB (0.66) | MAPK8MAPK9MAPK10HRH3 | |
| SCHEMBL2852389 | 0.67 | HRH3 (0.69) | HRH3 | |
| SCHEMBL3718784 | 0.67 | HRH3 (0.69) | HRH3 | |
| Hydrochloric Acid SCHEMBL2852644 | 0.66 | HRH3 (0.68) | HRH3 | |
| SCHEMBL3782542 | 0.66 | HRH3 (0.68) | HRH3 | |
| SCHEMBL14287829 | 0.63 | HRH3 (0.66) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | claimed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | claimed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | claimed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | claimed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | IMAGO PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3509586-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | Imago Pharmaceuticals, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9796706-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | MAP3K20, MYLK2, MAP3K8 | MAPK8 28/4885MAPK9 67/4885MAPK10 33/4885 |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.